 <h1>Kanuma Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>sebelipase alfa</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about sebelipase alfa. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kanuma.</p><h2>In Summary</h2><p><b>Common side effects of Kanuma include:</b> diarrhea, fever, vomiting, hypersensitivity reaction, and urticaria. <b>Other side effects include:</b> nausea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sebelipase alfa: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, sebelipase alfa (the active ingredient contained in Kanuma) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking sebelipase alfa:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>anxiety or agitation</li>
<li>blurred vision</li>
<li>chills</li>
<li>coughing</li>
<li>diarrhea</li>
<li>difficulty with breathing or swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, or rash</li>
<li>hoarseness</li>
<li>hyperventilation</li>
<li>irregular heartbeats</li>
<li>irritability</li>
<li>nausea</li>
<li>nervousness</li>
<li>paleness of the skin</li>
<li>pounding in the ears</li>
<li>reddening of the skin, especially around the ears</li>
<li>restlessness</li>
<li>shaking</li>
<li>skin rash, encrusted, scaly, and oozing</li>
<li>slow or fast heartbeat</li>
<li>slow or irregular breathing</li>
<li>swelling of the eyes, face, inside of the nose, or throat</li>
<li>tightness in the chest</li>
<li>vomiting</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest discomfort</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid shallow breathing</li>
<li>redness of the skin</li>
<li>redness of the white part of the eyes</li>
<li>swelling of the eyelids</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of sebelipase alfa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement (stool)</li>
<li>muscle aches</li>
<li>pale skin</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sebelipase alfa: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, hyperemia, hypotension</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Hypertension, pallor, increased blood pressure, increased heart rate</p>
<p>-Frequency not reported: Tachycardia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Urticaria, rash, pruritus, eczema, papular rash, pruritic rash</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Urticaria (33%), rash, eczema, pruritus, maculopapular rash<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, abdominal pain, abdominal distention, constipation</p>
<p><b>Frequency not reported</b>: Retching</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Diarrhea (67%), vomiting (67%), gastroesophageal reflux disease, retching<sup>[Ref]</sup></p><h3>General</h3><p>In clinical trials, 106 patients (total) were treated with this drug.  In 66 pediatric and adult patients with lysosomal acid lipase (LAL) deficiency, 36 patients received this drug (1 mg/kg IV every other week) while 30 patients received placebo during the double-blind period of the trial; age at first dose was 4 to 58 years.  Infants with evidence of rapidly progressive LAL deficiency before 6 months of age (n=9) received up to 3 mg/kg IV once a week; age at first dose was 1 to 6 months.</p>
<p></p>
<p>The most serious side effects reported in clinical studies were signs/symptoms consistent with anaphylaxis (including chest discomfort, conjunctival injection, dyspnea, generalized and itchy rash, hyperemia, mild eyelid edema, rhinorrhea, severe respiratory distress, tachycardia, tachypnea, urticaria).<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, menorrhagia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Anemia (44%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>In clinical trials, signs/symptoms of anaphylaxis were reported in 3 of 106 patients treated with this drug (including 2 of 92 children and adults and 1 of 14 infants).  Anaphylaxis was reported during infusion up to 1 year after the start of therapy.</p>
<p></p>
<p>In clinical trials, signs/symptoms of hypersensitivity reaction were reported in 21 of 106 patients treated with this drug (including 12 of 92 children and adults and 9 of 14 infants); such signs/symptoms occurred in at least 2 patients and included abdominal pain, agitation, chills, diarrhea, eczema, hypertension, irritability, laryngeal edema, nausea, edema, pallor, pruritus, pyrexia/increased body temperature, rash, tachycardia, urticaria, and vomiting.  Most reactions occurred during or within 4 hours of completing the infusion.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypersensitivity reaction</p>
<p><b>Common</b> (1% to 10%): Anaphylactic reaction</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Hypersensitivity reaction, anaphylaxis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antidrug antibodies (ADA) developed (14%)</p>
<p><b>Common</b> (1% to 10%): Neutralizing antibody development</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Antidrug antibodies developed (57%), positive for neutralizing antibodies<sup>[Ref]</sup></p><p>During a double-blind study, 5 out of 35 pediatric and adult patients treated with this drug developed ADA.  During the open-label extension, 2 patients developed in vitro neutralizing antibodies.</p>
<p></p>
<p>ADA developed in 4 of 7 patients with rapidly progressive LAL deficiency presenting with the first 6 months of life; 2 of the 4 ADA-positive patients were positive for neutralizing antibodies.  Hypersensitivity reactions were reported in all 4 ADA-positive patients compared to 1 of the 3 ADA-negative patients.  Decreased growth velocity (in a setting of neutralizing antibodies to this drug) was reported in 1 patient.</p>
<p></p>
<p>There was no clear association between the development of ADA and decreased efficacy of this drug.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increases in LDL cholesterol (LDL-c) and triglycerides above pretreatment levels were observed in 29 of 36 and 21 of 36 patients, respectively, at 2 and 4 weeks following initiation of this drug.  The maximum mean percentage increase for LDL-c at week 2 was 18% and 5% for triglycerides at week 4.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased low-density lipoprotein (LDL) cholesterol (81%), increased triglycerides (58%)</p>
<p><b>Common</b> (1% to 10%): Transient hypercholesterolemia, transient hypertriglyceridemia</p>
<p><b>Frequency not reported</b>: Oxygen saturation decreased</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Oxygen saturation decreased<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), hypotonia</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Frequency not reported: Hypotonia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Eyelid edema, conjunctival injection</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Eyelid edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/pyrexia (25%), oxygen saturation decreased</p>
<p><b>Common</b> (1% to 10%): Chills, chest discomfort, edema, fatigue, body temperature increased, infusion site induration, infusion related reaction, asthenia</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Fever/pyrexia (56%), catheter site/device related infection (33%), increased body temperature, chills, edema, hyperthermia, irritability, decreased growth velocity, oxygen saturation decreased<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Agitation, irritability<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (17%), nasopharyngitis (11%), sneezing</p>
<p><b>Common</b> (1% to 10%): Laryngeal edema, dyspnea, rhinorrhea, severe respiratory distress, tachypnea</p>
<p><b>Frequency not reported</b>: Nasal congestion, sneezing, wheezing</p>
<p></p>
<p>Rapidly Progressive LAL Deficiency:</p>
<p>-Very common (10% or more): Rhinitis (56%), nasopharyngitis (33%), cough (33%), respiratory distress, wheezing, nasal congestion, increased respiratory rate, nasal congestion, sneezing<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Kanuma (sebelipase alfa)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Kanuma (sebelipase alfa)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kanuma &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Lysosomal Acid Lipase Deficiency</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sebelipase alfa: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, hyperemia, hypotension</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Hypertension, pallor, increased blood pressure, increased heart rate</p><p>-Frequency not reported: Tachycardia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Urticaria, rash, pruritus, eczema, papular rash, pruritic rash</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Urticaria (33%), rash, eczema, pruritus, maculopapular rash<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, abdominal pain, abdominal distention, constipation</p><p><b>Frequency not reported</b>: Retching</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Diarrhea (67%), vomiting (67%), gastroesophageal reflux disease, retching<sup>[Ref]</sup></p><h3>General</h3><p>In clinical trials, 106 patients (total) were treated with this drug.  In 66 pediatric and adult patients with lysosomal acid lipase (LAL) deficiency, 36 patients received this drug (1 mg/kg IV every other week) while 30 patients received placebo during the double-blind period of the trial; age at first dose was 4 to 58 years.  Infants with evidence of rapidly progressive LAL deficiency before 6 months of age (n=9) received up to 3 mg/kg IV once a week; age at first dose was 1 to 6 months.</p><p></p><p>The most serious side effects reported in clinical studies were signs/symptoms consistent with anaphylaxis (including chest discomfort, conjunctival injection, dyspnea, generalized and itchy rash, hyperemia, mild eyelid edema, rhinorrhea, severe respiratory distress, tachycardia, tachypnea, urticaria).<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, menorrhagia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Anemia (44%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>In clinical trials, signs/symptoms of anaphylaxis were reported in 3 of 106 patients treated with this drug (including 2 of 92 children and adults and 1 of 14 infants).  Anaphylaxis was reported during infusion up to 1 year after the start of therapy.</p><p></p><p>In clinical trials, signs/symptoms of hypersensitivity reaction were reported in 21 of 106 patients treated with this drug (including 12 of 92 children and adults and 9 of 14 infants); such signs/symptoms occurred in at least 2 patients and included abdominal pain, agitation, chills, diarrhea, eczema, hypertension, irritability, laryngeal edema, nausea, edema, pallor, pruritus, pyrexia/increased body temperature, rash, tachycardia, urticaria, and vomiting.  Most reactions occurred during or within 4 hours of completing the infusion.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypersensitivity reaction</p><p><b>Common</b> (1% to 10%): Anaphylactic reaction</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Hypersensitivity reaction, anaphylaxis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antidrug antibodies (ADA) developed (14%)</p><p><b>Common</b> (1% to 10%): Neutralizing antibody development</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Antidrug antibodies developed (57%), positive for neutralizing antibodies<sup>[Ref]</sup></p><p>During a double-blind study, 5 out of 35 pediatric and adult patients treated with this drug developed ADA.  During the open-label extension, 2 patients developed in vitro neutralizing antibodies.</p><p></p><p>ADA developed in 4 of 7 patients with rapidly progressive LAL deficiency presenting with the first 6 months of life; 2 of the 4 ADA-positive patients were positive for neutralizing antibodies.  Hypersensitivity reactions were reported in all 4 ADA-positive patients compared to 1 of the 3 ADA-negative patients.  Decreased growth velocity (in a setting of neutralizing antibodies to this drug) was reported in 1 patient.</p><p></p><p>There was no clear association between the development of ADA and decreased efficacy of this drug.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increases in LDL cholesterol (LDL-c) and triglycerides above pretreatment levels were observed in 29 of 36 and 21 of 36 patients, respectively, at 2 and 4 weeks following initiation of this drug.  The maximum mean percentage increase for LDL-c at week 2 was 18% and 5% for triglycerides at week 4.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased low-density lipoprotein (LDL) cholesterol (81%), increased triglycerides (58%)</p><p><b>Common</b> (1% to 10%): Transient hypercholesterolemia, transient hypertriglyceridemia</p><p><b>Frequency not reported</b>: Oxygen saturation decreased</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Oxygen saturation decreased<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), hypotonia</p><p><b>Common</b> (1% to 10%): Dizziness</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Frequency not reported: Hypotonia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Eyelid edema, conjunctival injection</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Eyelid edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/pyrexia (25%), oxygen saturation decreased</p><p><b>Common</b> (1% to 10%): Chills, chest discomfort, edema, fatigue, body temperature increased, infusion site induration, infusion related reaction, asthenia</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Fever/pyrexia (56%), catheter site/device related infection (33%), increased body temperature, chills, edema, hyperthermia, irritability, decreased growth velocity, oxygen saturation decreased<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Agitation, irritability<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (17%), nasopharyngitis (11%), sneezing</p><p><b>Common</b> (1% to 10%): Laryngeal edema, dyspnea, rhinorrhea, severe respiratory distress, tachypnea</p><p><b>Frequency not reported</b>: Nasal congestion, sneezing, wheezing</p><p></p><p>Rapidly Progressive LAL Deficiency:</p><p>-Very common (10% or more): Rhinitis (56%), nasopharyngitis (33%), cough (33%), respiratory distress, wheezing, nasal congestion, increased respiratory rate, nasal congestion, sneezing<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Kanuma (sebelipase alfa)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p><h2>More about Kanuma (sebelipase alfa)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kanuma &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Lysosomal Acid Lipase Deficiency</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>